Navigation Links
Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy

Intravascular Ultrasound Demonstrates Utility in Evaluating Drug Efficacy; Dr. H. Bryan Brewer, Jr. Sees Enormous Potential for HDL Therapy

PLEASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX News Network) -- Lipid Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer, Jr., Chief Scientific Director of Lipid Sciences, Inc., concluded from the wide range of presentations at the recent American College of Cardiology (ACC) Meeting in New Orleans that the rationale for HDL being the next, most logical target for the development of treatments for cardiovascular disease continues to exhibit enormous potential. This conclusion is even more compelling in light of the recent, highly publicized failure of the CETP inhibitor, torcetrapib.

This week at the ACC meeting, the latest data on three imaging trials, which included an intravascular ultrasound (IVUS) study, with Pfizer's HDL raising drug, torcetrapib were presented. Torcetrapib is a member of a class of drugs which increase HDL by inhibiting the cholesterol ester transfer protein (CETP). ILLUMINATE, a morbidity and mortality trial comparing the clinical efficacy and safety of torcetrapib/atorvastatin (Lipitor) versus atorvastatin alone was terminated in December 2006 due to an increased number of deaths in those patients taking torcetrapib/atorvastatin. It is important to note that the three imaging trials also failed to show a benefit of torcetrapib/atorvastatin when compared to atorvastatin alone and were consistent with the lack of efficacy that was observed.

Dr. Brewer noted, "The results obtained in the ILLUMINATE trial and the three imaging trials, while unexpected, do not reflect on the potential clinical benefit of raising HDL. Statin drugs have a proven clinical benefit in reducing heart attacks and stroke; however, the reduction in these clinical events is, at best, only approximately one third. A significant number of patien
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Inspire Announces Presentations at Two European Scientific Conferences
6. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
7. IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting
8. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
11. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
Post Your Comments:
(Date:7/23/2008)...nds Some Areas of the Body Have Greater Concentrat... 23 /PRNewswire-USNewswire/ -- Fat removed,from th...n was found to be,an excellent source of stem cell... areas of the body, reports a Brazilian-based stud...), the official medical journal of the,American So...
(Date:7/22/2008)...tralia, July 22 /- Followin... the Board of Progen,Pharmaceuticals Limited (ASX:...scontinued the PI-88 phase 3 study in liver cancer...lop its existing portfolio of compounds and,the co...pounds and,opportunities through Merger & Acquisit...
(Date:7/22/2008)...g to Discuss Development Plan Completed Successful...l/ -- Amarin Corporation,plc (NASDAQ: AMRN ) toda...icials at the U.S. Food and Drug Administration (F...01 for the treatment of,hypertriglyceridemia. Foll... to Phase 3 with AMR101 in hypertriglyceridemia., ...
(Date:7/22/2008)...llan Will Stress the Importance to Patients of Pas...al Pathway, RICHMOND, Va., July 22 /PRNewswire-Fi...per of follow-on biologics and biopharmaceuticals,...f Insmed, will present at a,Congressional briefing...cant need for establishing an approval pathway for...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 1Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 10496 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 1Markets of biodiversity and equity in trade 3A An illusion 3F 2058 2Markets of biodiversity and equity in trade 3A An illusion 3F 2058 3American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 1American Journal of Disaster Medicine Accepted for Inclusion into The National Library of Medicines MEDLINE Database and may now be Accessed Through t 10495 2Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 1Life 3AWIRE 28TM 29 to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 10492 2
... /PRNewswire-FirstCall/ -- Iomai,Corporation today...Phase 1 trial of its patch-based needle-free influ...onference call and live,webcast will be held at 8:...ts. , Conference Call Details , To access the live... Eastern Time via phone, please dial 888-396-2356 ...
... 2007 - HepaLife Technologies, Inc.,(OTCBB:HPLF) (...entific presentation of its cell based PBS-1 techn...t the "Options for the,Control of Influenza VI Con... Canada., Entitled "High titer growth of human and...embryo cell line without the need for,exogenous pr...
Other Medicine Technology:Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 2HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 3HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 4HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting 5
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
... (SARS) epidemic in China has lessons to teach hos...ratory diseases// , according to new research appe... Diseases, currently available online. Hospitals ...n Guangzhou province and Hong Kong in 2003. In hos...
...fresh attack on genetically modified maize develop...ay that rats// fed on one version developed liver ...ad commissioned that was published in the journal ...n and Technology showed rats fed for 90 days on Mo...
...fying agent which could make vaccines for the H5N1...r to produce//. The development could help develo...ndemic struggling to access and afford the vaccine...ockpiled by developed countries. Researchers from...
... junk food in school canteens following a report b...DDRC in its report// has shown concern about the i...betes. A survey carried out by DDRC in 38 schools...n is clinically unhealthy or obese and junk food r...
Other Medicine News:Health News:Study Identifies Risk Factors for Spread of Respiratory Infections in Hospitals 2Health News:Brazilian Boost for Bird Flu Vaccines 2Health News:Brazilian Boost for Bird Flu Vaccines 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens
Medicine Products: